Treatment of HIV in the central nervous system

Seminars in Neurology

Volumn 34, Issue 1, 2014, Pages 14-20

  Yilmaz, Aylin ^a   Gisslén, Magnus ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

antiretroviral treatment; central nervous system; human immunodeficiency disease

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; DRUG EFFECT; DRUG PENETRATION; EARLY INTERVENTION; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROTOXICITY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SYSTEMIC THERAPY; CENTRAL NERVOUS SYSTEM DISEASES; COGNITION DISORDERS; COMPLICATION; HIV INFECTIONS; VIROLOGY;

CENTRAL NERVOUS SYSTEM DISEASES; COGNITION DISORDERS; HIV INFECTIONS; HUMANS;

EID: 84898471020     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0034-1372338     Document Type: Article

References (96)

1. Davis L. E., Hjelle B. L., Miller V. E., et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology: 1992; 42 9 1736 1739
2. Spudich S., Gisslen M., Hagberg L., et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis: 2011; 204 5 753 760
3. Valcour V., Chalermchai T., Sailasuta N., et al. RV254/SEARCH 010 Study Group. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis: 2012; 206 2 275 282
4. Conrad A. J., Schmid P., Syndulko K., et al. Quantifying HIV-1 RNA using the polymerase chain reaction on cerebrospinal fluid and serum of seropositive individuals with and without neurologic abnormalities. J Acquir Immune Defic Syndr Hum Retrovirol: 1995; 10 4 425 435
5. Gisslén M., Fuchs D., Svennerholm B., Hagberg L. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr: 1999; 21 4 271 276 (Pubitemid 29357657)
6. Spudich S. S., Nilsson A. C., Lollo N. D., et al. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis: 2005; 5 98
7. Price R. W., Brew B. J. The AIDS dementia complex. J Infect Dis: 1988; 158 5 1079 1083 (Pubitemid 18266060)
8. Portegies P., de Gans J., Lange J. M., et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ: 1989; 299 6703 819 821 (Pubitemid 19235939)
9. Brew B. J., Rosenblum M., Price R. W. AIDS dementia complex and primary HIV brain infection. J Neuroimmunol: 1988; 20 2-3 133 140 (Pubitemid 19008399)
10. Heaton R. K., Clifford D. B., Franklin D. R. Jr., et al. CHARTER Group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology: 2010; 75 23 2087 2096
11. Heaton R. K., Franklin D. R., Ellis R. J., et al. CHARTER Group; HNRC Group. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol: 2011; 17 1 3 16
12. Sinclair E., Ronquillo R., Lollo N., et al. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr: 2008; 47 5 544 552 (Pubitemid 351442007)
13. Yilmaz A., Price R. W., Gisslén M. Antiretroviral drug treatment of CNS HIV-1 infection. J Antimicrob Chemother: 2012; 67 2 299 311
14. Engelhardt B., Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol: 2009; 31 4 497 511
15. Chiodi F., Keys B., Albert J., et al. Human immunodeficiency virus type 1 is present in the cerebrospinal fluid of a majority of infected individuals. J Clin Microbiol: 1992; 30 7 1768 1771
16. Schnell G., Spudich S., Harrington P., Price R. W., Swanstrom R. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog: 2009; 5 4 e1000395
17. Schnell G., Price R. W., Swanstrom R., Spudich S. Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J Virol: 2010; 84 5 2395 2407
18. Hazenberg M. D., Otto S. A., Wit F. W., Lange J. M., Hamann D., Miedema F. Discordant responses during antiretroviral therapy: role of immune activation and T cell redistribution rather than true CD4 T cell loss. AIDS: 2002; 16 9 1287 1289 (Pubitemid 34666665)
19. Ransohoff R. M., Kivisäkk P., Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol: 2003; 3 7 569 581 (Pubitemid 37328676)
20. Smit T. K., Brew B. J., Tourtellotte W., Morgello S., Gelman B. B., Saksena N. K. Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol: 2004; 78 18 10133 10148 (Pubitemid 39187131)
21. Cysique L. A., Maruff P., Brew B. J. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology: 2006; 66 9 1447 1450 (Pubitemid 43739663)
22. Ellis R. J., Badiee J., Vaida F., et al. CHARTER Group. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS: 2011; 25 14 1747 1751
23. Abdulle S., Mellgren A., Brew B. J., et al. CSF neurofilament protein (NFL)-a marker of active HIV-related neurodegeneration. J Neurol: 2007; 254 8 1026 1032 (Pubitemid 47353414)
24. Crum-Cianflone N. F., Moore D. J., Letendre S., et al. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology: 2013; 80 4 371 379
25. Sailasuta N., Ross W., Ananworanich J., et al. RV254/SEARCH 010 protocol teams. Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. PLoS ONE: 2012; 7 11 e49272
26. Anthony I. C., Ramage S. N., Carnie F. W., Simmonds P., Bell J. E. Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol: 2005; 64 6 529 536 (Pubitemid 40781156)
27. Edén A., Price R. W., Spudich S., Fuchs D., Hagberg L., Gisslén M. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis: 2007; 196 12 1779 1783 (Pubitemid 351411938)
28. Harezlak J., Buchthal S., Taylor M., et al. HIV Neuroimaging Consortium. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS: 2011; 25 5 625 633
29. Yilmaz A., Yiannoutsos C. T., Fuchs D., et al. Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation: 2013; 10 62
30. Takasawa K., Terasaki T., Suzuki H., Ooie T., Sugiyama Y. Distributed model analysis of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. J Pharmacol Exp Ther: 1997; 282 3 1509 1517 (Pubitemid 27408335)
31. Best B. M., Letendre S. L., Koopmans P., et al. CHARTER Study Group. Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr: 2012; 59 4 376 381
32. Foudraine N. A., Hoetelmans R. M., Lange J. M., et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet: 1998; 351 9115 1547 1551 (Pubitemid 28230890)
33. Best B. M., Koopmans P. P., Letendre S. L., et al. CHARTER Group. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother: 2011; 66 2 354 357
34. van Praag R. M., van Weert E. C., van Heeswijk R. P., et al. Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy. Antimicrob Agents Chemother: 2002; 46 3 896 899 (Pubitemid 34157685)
35. Nguyen A., Rossi S., Croteau D., et al. CHARTER Group. Etravirine in CSF is highly protein bound. J Antimicrob Chemother: 2013; 68 5 1161 1168
36. Mora-Peris B., Watson V., Vera J., et al. Rilpivirine concentrations in plasma and cerebrospinal fluid after switching from nevirapine-containing cART. Paper presented at: 14th International Workshop on Clinical Pharmacology of HIV Therapy; April 22-24, 2013; Amsterdam, the Netherlands
37. Kim R. B., Fromm M. F., Wandel C., et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest: 1998; 101 2 289 294 (Pubitemid 28067324)
38. Vernazza P., Daneel S., Schiffer V., et al. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS: 2007; 21 10 1309 1315 (Pubitemid 46883485)
39. Katlama C., Valantin M. A., Algarte-Genin M., et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS: 2010; 24 15 2365 2374
40. Meynard J. L., Bouteloup V., Landman R., et al. KALESOLO Study Group. Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial. J Antimicrob Chemother: 2010; 65 11 2436 2444
41. Lafeuillade A., Solas C., Halfon P., Chadapaud S., Hittinger G., Lacarelle B. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials: 2002; 3 1 27 35 (Pubitemid 34183093)
42. Gutmann C., Cusini A., Günthard H. F., et al. Swiss HIV Cohort Study (SHCS). Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS: 2010; 24 15 2347 2354
43. Haas D. W., Clough L. A., Johnson B. W., et al. Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. AIDS Res Hum Retroviruses: 2000; 16 15 1491 1502
44. Yilmaz A., Fuchs D., Hagberg L., et al. Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study. BMC Infect Dis: 2006; 6 63
45. Karlström O., Ståhle L., Perrin L., Tegude H., Sönnerborg A. Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients. Scand J Infect Dis: 2006; 38 5 371 374 (Pubitemid 43832404)
46. Moyle G. J., Sadler M., Buss N. Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy. Clin Infect Dis: 1999; 28 2 403 404 (Pubitemid 29241233)
47. Saumoy M., Tiraboschi J., Gutierrez M., et al. Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study). HIV Med: 2011; 12 7 438 441
48. Letendre S., Mills A., Tashima K., et al. Distribution and antiviral activity in cerebrospinal fluid of the integrase inhibitor, dolutegravir: ING116070 Week 16 results. Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections, March-6, 2013; Atlanta, GA
49. Yilmaz A., Gisslén M., Spudich S., et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS ONE: 2009; 4 9 e6877
50. Calcagno A., Bonora S., Bertucci R., Lucchini A., D'Avolio A., Di Perri G. Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. AIDS: 2010; 24 6 931 932
51. Moore J. P., Doms R. W. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci U S A: 2003; 100 19 10598 10602 (Pubitemid 37140074)
52. Price R. W., Parham R., Kroll J. L., et al. Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. Antivir Ther: 2008; 13 3 369 374 (Pubitemid 352016729)
53. Thomas S. A. Drug transporters relevant to HIV therapy. J HIV Ther: 2004; 9 4 92 96
54. Yilmaz A., Watson V., Else L., Gisslèn M. Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS: 2009; 23 18 2537 2540
55. Tiraboschi J. M., Niubo J., Curto J., Podzamczer D. Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients. J Acquir Immune Defic Syndr: 2010; 55 5 606 609
56. Letendre S., Marquie-Beck J., Capparelli E., et al. CHARTER Group. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol: 2008; 65 1 65 70
57. Gisslén M., Hagberg L., Svennerholm B., Norkrans G. HIV-1 RNA is not detectable in the cerebrospinal fluid during antiretroviral combination therapy. AIDS: 1997; 11 9 1194 (Pubitemid 27273624)
58. Mellgren A., Antinori A., Cinque P., et al. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther: 2005; 10 6 701 707 (Pubitemid 41376848)
59. Eggers C., Hertogs K., Stürenburg H. J., van Lunzen J., Stellbrink H. J. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS: 2003; 17 13 1897 1906 (Pubitemid 37070275)
60. Staprans S., Marlowe N., Glidden D., et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS: 1999; 13 9 1051 1061 (Pubitemid 29361395)
61. Ellis R. J., Gamst A. C., Capparelli E., et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology: 2000; 54 4 927 936 (Pubitemid 30111354)
62. Gisslén M., Svennerholm B., Norkrans G., et al. Cerebrospinal fluid and plasma viral load in HIV-1-infected patients with various anti-retroviral treatment regimens. Scand J Infect Dis: 2000; 32 4 365 369 (Pubitemid 30612150)
63. Yilmaz A., Price R. W., Spudich S., Fuchs D., Hagberg L., Gisslén M. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr: 2008; 47 2 168 173 (Pubitemid 351172183)
64. Spudich S., Lollo N., Liegler T., Deeks S. G., Price R. W. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis: 2006; 194 12 1686 1696 (Pubitemid 44901999)
65. Dinoso J. B., Kim S. Y., Wiegand A. M., et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A: 2009; 106 23 9403 9408
66. Dahl V., Lee E., Peterson J., et al. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis: 2011; 204 12 1936 1945
67. Yilmaz A., Verhofstede C., D'Avolio A., et al. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr: 2010; 55 5 590 596
68. Mellgren A., Price R. W., Hagberg L., Rosengren L., Brew B. J., Gisslén M. Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection. Neurology: 2007; 69 15 1536 1541 (Pubitemid 47537861)
69. Hagberg L., Cinque P., Gisslen M., et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther: 2010; 7 15
70. Abdulle S., Hagberg L., Svennerholm B., Fuchs D., Gisslén M. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS: 2002; 16 16 2145 2149 (Pubitemid 35387268)
71. Abdulle S., Hagberg L., Gisslén M. Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients. HIV Med: 2005; 6 3 164 169 (Pubitemid 40740332)
72. McArthur J. C., Steiner J., Sacktor N., Nath A. Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. Ann Neurol: 2010; 67 6 699 714
73. Hunt P. W. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep: 2012; 9 2 139 147
74. Canestri A., Lescure F. X., Jaureguiberry S., et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis: 2010; 50 5 773 778
75. Peluso M. J., Ferretti F., Peterson J., et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS: 2012; 26 14 1765 1774
76. Lescure F. X., Moulignier A., Savatovsky J., et al. CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity. Clin Infect Dis: 2013; 57 1 101 108
77. Gray F., Lescure F. X., Adle-Biassette H., et al. Encephalitis with infiltration by CD8+ lymphocytes in HIV patients receiving combination antiretroviral treatment. Brain Pathol: 2013; 23 5 525 533
78. Edén A., Fuchs D., Hagberg L., et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis: 2010; 202 12 1819 1825
79. Lescure F. X., Omland L. H., Engsig F. N., et al. Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis: 2011; 52 2 235 243
80. Andersson L. M., Hagberg L., Rosengren L., Fuchs D., Blennow K., Gisslén M. Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia-case report. BMC Infect Dis: 2006; 6 141
81. d'Arminio Monforte A., Cinque P., Mocroft A., et al. EuroSIDA Study Group. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol: 2004; 55 3 320 328 (Pubitemid 38292033)
82. Robertson K. R., Smurzynski M., Parsons T. D., et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS: 2007; 21 14 1915 1921 (Pubitemid 47329768)
83. Simioni S., Cavassini M., Annoni J. M., et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS: 2010; 24 9 1243 1250
84. Pumpradit W., Ananworanich J., Lolak S., et al. Southeast Asia Research Collaboration with Hawaii (SEARCH) 005 Protocol Team. Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study. J Neurovirol: 2010; 16 1 76 82
85. Bonnet F., Amieva H., Marquant F., et al. S CO3 Aquitaine Cohort. Cognitive disorders in HIV-infected patients: are they HIV-related? AIDS: 2013; 27 3 391 400
86. Cysique L. A., Brew B. J. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol: 2011; 17 2 176 183
87. Muñoz-Moreno J. A., Fumaz C. R., Ferrer M. J., et al. Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses: 2008; 24 10 1301 1307
88. Gisslen M., Hagberg L., Rosengren L., et al. Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol: 2007; 2 1 112 119
89. Adkins J. C., Noble S. Efavirenz. Drugs: 1998; 56 6 1055 1064, discussion 1065-1066 (Pubitemid 29011722)
90. Lochet P., Peyrière H., Lotthé A., Mauboussin J. M., Delmas B., Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med: 2003; 4 1 62 66 (Pubitemid 37161538)
91. Clifford D. B., Evans S., Yang Y., Acosta E. P., Ribaudo H., Gulick R. M.; A5097s Study Team. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials: 2009; 10 6 343 355
92. Robertson K. R., Su Z., Margolis D. M., et al. A5170 Study Team. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology: 2010; 74 16 1260 1266
93. Marra C. M., Zhao Y., Clifford D. B., et al. AIDS Clinical Trials Group 736 Study Team. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS: 2009; 23 11 1359 1366
94. Alton E. W., Stern M., Farley R., et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet: 1999; 353 9157 947 954 (Pubitemid 29132602)
95. Tovar-y-Romo L. B., Bumpus N. N., Pomerantz D., et al. Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther: 2012; 343 3 696 703
96. Robertson K., Liner J., Meeker R. B. Antiretroviral neurotoxicity. J Neurovirol: 2012; 18 5 388 399